Exogenous surfactant therapy in 2013: what is next? who, when and how should we treat newborn infants in the future?

BMC Pediatrics

for the French Young Neonatologist Club  Olivier Baud⁵  Pierre Tourneux²  Mona Merhi³  Cyril Flamant¹  Géraldine Gascoin⁴  Emmanuel Lopez⁶ 

[1] Département de pédecine néonatale, CHU de Nantes, Nantes, France;Médecine Néonatale, CHU d’Amiens, Amiens, France;Réanimation Néonatale, CH Sud Francilien, Corbeil-Essonnes, France;Réanimation et Médecine Néonatales, CHU d’Angers, Angers, France;Réanimation et Pédiatrie Néonatales, Groupe Hospitalier Robert Debré, APHP, 48 Bd Sérurier, Paris, 75019, France;Service de Médecine Néonatale de Port-Royal Groupe Hospitalier Cochin-Broca-Hôtel Dieu, APHP, Paris, France

关键词: Review;    Critical care;    Developing lung;    Respiratory distress;    Neonate;    Surfactant;   

Others  :  1144443
DOI  :  10.1186/1471-2431-13-165

 received in 2013-05-22, accepted in 2013-09-19,  发布年份 2013

【 摘 要 】

Background

Surfactant therapy is one of the few treatments that have dramatically changed clinical practice in neonatology. In addition to respiratory distress syndrome (RDS), surfactant deficiency is observed in many other clinical situations in term and preterm infants, raising several questions regarding the use of surfactant therapy.

Objectives

This review focuses on several points of interest, including some controversial or confusing topics being faced by clinicians together with emerging or innovative concepts and techniques, according to the state of the art and the published literature as of 2013. Surfactant therapy has primarily focused on RDS in the preterm newborn. However, whether this treatment would be of benefit to a more heterogeneous population of infants with lung diseases other than RDS needs to be determined. Early trials have highlighted the benefits of prophylactic surfactant administration to newborns judged to be at risk of developing RDS. In preterm newborns that have undergone prenatal lung maturation with steroids and early treatment with continuous positive airway pressure (CPAP), the criteria for surfactant administration, including the optimal time and the severity of RDS, are still under discussion. Tracheal intubation is no longer systematically done for surfactant administration to newborns. Alternative modes of surfactant administration, including minimally-invasive and aerosolized delivery, could thus allow this treatment to be used in cases of RDS in unstable preterm newborns, in whom the tracheal intubation procedure still poses an ethical and medical challenge.

Conclusion

The optimization of the uses and methods of surfactant administration will be one of the most important challenges in neonatal intensive care in the years to come.

【 授权许可】

   
2013 Lopez et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Enhörning G, Robertson B: Lung expansion in the premature rabbit fetus after tracheal deposition of surfactant. Pediatrics 1972, 50:58-66.
• [2]Soll R, Ozek E: Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2010., 1CD001079
• [3]Soll RF: Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2000., 2CD001079
• [4]Bahadue FL, Soll R: Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev 2012., 11CD001456
• [5]Rojas-Reyes MX, Morley CJ, Soll R: Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2012., 3CD000510
• [6]Carbajal R, Eble B, Anand KJ: Premedication for tracheal intubation in neonates: confusion or controversy? Semin Perinatol 2007, 31:309-317.
• [7]Durrmeyer X, Vutskits L, Anand KJ, Rimensberger PC: Use of analgesic and sedative drugs in the NICU: integrating clinical trials and laboratory data. Pediatr Res 2010, 67:117-127.
• [8]Drasner K: Anesthetic effects on the developing nervous system: if you aren’t concerned, you haven’t been paying attention. Anesthesiology 2010, 113:10-12.
• [9]Dunn MS, Shennan AT, Zayack D, Possmayer F: Bovine surfactant replacement therapy in neonates of less than 30 weeks’ gestation: a randomized controlled trial of prophylaxis versus treatment. Pediatrics 1991, 87:377-386.
• [10]Osborn DA, Jeffery HE, Bredemeyer SL, Polverino JM, Reid S: Targeted early rescue surfactant in ventilated preterm infants using the click test. Pediatrics 2000, 106:E30.
• [11]Robert MF, Neff RK, Hubbell JP, Taeusch HW, Avery ME: Association between maternal diabetes and the respiratory-distress syndrome in the newborn. N Engl J Med 1976, 294:357-360.
• [12]Delgado JC, Greene MF, Winkelman JW, Tanasijevic MJ: Comparison of disaturated phosphatidylcholine and fetal lung maturity surfactant/albumin ratio in diabetic and nondiabetic pregnancies. Am J Clin Pathol 2000, 113:233-239.
• [13]Tsai MY, Shultz EK, Williams PP, Bendel R, Butler J, Farb H, Wager G, Knox EG, Julian T, Thompson TR: Assay of disaturated phosphatidylcholine in amniotic fluid as a test of fetal lung maturity: experience with 2000 analyses. Clin Chem 1987, 33:1648-1651.
• [14]Epaud R, Jonard L, Ducou-le-Pointe H, Delestrain C, Fanen P, Guillot L, Flamein F: Genetic disorders of surfactant. Arch Pediatr 2012, 19:212-219.
• [15]Gower WA, Nogee LM: Surfactant dysfunction. Paediatr Respir Rev 2011, 12:223-229.
• [16]Nogee LM, de Mello DE, Dehner LP, Colten HR: Deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med 1993, 328:406-410.
• [17]Nogee LM, Dunbar AE 3rd, Wert SE, Askin F, Hamvas A, Whitsett JA: A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001, 344:573-579.
• [18]Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M: ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med 2004, 350:1296-1303.
• [19]Guillot L, Carré A, Szinnai G, Castanet M, Tron E, Jaubert F, Broutin I, Counil F, Feldmann D, Clement A, Polak M, Epaud R: NKX2-1 mutations leading to surfactant protein promoter dysregulation cause interstitial lung disease in “brain-lung-thyroid syndrome”. Hum Mutat 2010, 31:E1146-E1162.
• [20]Oh MH, Bae CW: Inhibitory effect of meconium on pulmonary surfactant function tested in vitro using the stable microbubble test. Eur J Pediatr 2000, 159:770-774.
• [21]Bissinger R, Carlson C, Hulsey T, Eicher D: Secondary surfactant deficiency in neonates. J Perinatol 2004, 24:663-666.
• [22]Angus DC, Linde-Zwirble WT, Clermont G, Griffin MF, Clark RH: Epidemiology of neonatal respiratory failure in the United States: projections from California and New York. Am J Respir Crit Care Med 2001, 164:1154-1160.
• [23]Hibbard JU, Wilkins I, Sun L, Gregory K, Haberman S, Hoffman M, Kominiarek MA, Reddy U, Bailit J, Branch DW, Burkman R, Gonzalez Quintero VH, Hatjis CG, Landy H, Ramirez M, VanVeldhuisen P, Troendle J, Zhang J, Consortium on Safe Labor: Respiratory morbidity in late preterm births. JAMA 2010, 304:419-425.
• [24]Morrison JJ, Rennie JM, Milton PJ: Neonatal respiratory morbidity and mode of delivery at term: influence of timing of elective caesarean section. Br J Obstet Gynaecol 1995, 102:101-106.
• [25]Zanardo V, Simbi AK, Franzoi M, Soldà G, Salvadori A, Trevisanuto D: Neonatal respiratory morbidity risk and mode of delivery at term: influence of timing of elective caesarean delivery. Acta Paediatr 2004, 93:643-647.
• [26]Clark RH: The epidemiology of respiratory failure in neonates born at an estimated gestational age of 34 weeks or more. J Perinatol 2005, 25:251-257.
• [27]Machado LU, Fiori HH, Baldisserotto M, Ramos Garcia PC, Vieira AC, Fiori RM: Surfactant deficiency in transient tachypnea of the newborn. J Pediatr 2011, 159:750-754.
• [28]Holm BA, Notter RH: Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity. J Appl Physiol 1987, 63:1434-1442.
• [29]Wang Z, Notter RH: Additivity of protein and nonprotein inhibitors of lung surfactant activity. Am J Respir Crit Care Med 1998, 158:28-35.
• [30]Pandit PB, Dunn MS, Colucci EA: Surfactant therapy in neonates with respiratory deterioration due to pulmonary hemorrhage. Pediatrics 1995, 95:32-36.
• [31]Amizuka T, Shimizu H, Niida Y, Ogawa Y: Surfactant therapy in neonates with respiratory failure due to haemorrhagic pulmonary oedema. Eur J Pediatr 2003, 162:697-702.
• [32]Neumayr TM, Watson AM, Wylam ME, Ouellette Y: Surfactant treatment of an infant with acute idiopathic pulmonary hemorrhage. Pediatr Crit Care Med 2008, 9:e4-e6.
• [33]Haas NA, Kulasekaran K, Camphausen CK: Successful use of surfactant to treat severe intrapulmonary hemorrhage after iatrogenic lung injury–a case report. Pediatr Crit Care Med 2006, 7:583-585.
• [34]Aziz A, Ohlsson A: Surfactant for pulmonary haemorrhage in neonates. Cochrane Database Syst Rev 2012., 7CD005254
• [35]Dargaville PA, Copnell B, Mills JF, Haron I, Lee JK, Tingay DG, Rohana J, Mildenhall LF, Jeng MJ, Narayanan A, Battin MR, Kuschel CA, Sadowsky JL, Patel H, Kilburn CJ, Carlin JB, Morley CJ, lessMAS Trial Study Group: Randomized controlled trial of lung lavage with dilute surfactant for meconium aspiration syndrome. J Pediatr 2011, 158:383-389.
• [36]Beligere N, Rao R: Neurodevelopmental outcome of infants with meconium aspiration syndrome: report of a study and literature review. J Perinatol 2008, 28:S93-S101.
• [37]Tyler DC, Murphy J, Cheney FW: Mechanical and chemical damage to lung tissue caused by meconium aspiration. Pediatrics 1978, 62:454-459.
• [38]Tran N, Lowe C, Sivieri EM, Shaffer TH: Sequential effects of acute meconium obstruction on pulmonary function. Pediatr Res 1980, 14:34-38.
• [39]Cleary GM, Antunes MJ, Ciesielka DA, Higgins ST, Spitzer AR, Chander A: Exudative lung injury is associated with decreased levels of surfactant proteins in a rat model of meconium aspiration. Pediatrics 1997, 100:998-1003.
• [40]Moses D, Holm BA, Spitale P, Liu MY, Enhorning G: Inhibition of pulmonary surfactant function by meconium. Am J Obstet Gynecol 1991, 164:477-481.
• [41]Bae CW, Takahashi A, Chida S, Sasaki M: Morphology and function of pulmonary surfactant inhibited by meconium. Pediatr Res 1998, 44:187-191.
• [42]Wiswell TE, Bley JA, Turner BS, Hunt RE, Fritz DL: Different high-frequency ventilator strategies: effect on the propagation of tracheobronchial histopathologic changes. Pediatrics 1990, 85:70-78.
• [43]Dargaville PA, Copnell B, Australian and New Zealand Neonatal Network: The epidemiology of meconium aspiration syndrome: incidence, risk factors, therapies, and outcome. Pediatrics 2006, 117:1712-1721.
• [44]El Shahed AI, Dargaville P, Ohlsson A, Soll RF: Surfactant for meconium aspiration syndrome in full term/near term infants. Cochrane Database Syst Rev 2007., 3CD002054
• [45]Dargaville PA, Mills JF, Headley BM, Chan Y, Coleman L, Loughnan PM, Morley CJ: Therapeutic lung lavage in the piglet model of meconium aspiration syndrome. Am J Respir Crit Care Med 2003, 168:456-463.
• [46]Lista G, Bianchi S, Castoldi F, Fontana P, Cavigioli F: Bronchoalveolar lavage with diluted porcine surfactant in mechanically ventilated term infants with meconium aspiration syndrome. Clin Drug Investig 2006, 26:13-19.
• [47]Dargaville PA, Mills JF, Copnell B, Loughnan PM, McDougall PN, Morley CJ: Therapeutic lung lavage in meconium aspiration syndrome: a preliminary report. J Paediatr Child Health 2007, 43:539-545.
• [48]Hahn S, Choi HJ, Soll R, Dargaville PA: Lung lavage for meconium aspiration syndrome in newborn infants. Cochrane Database Syst Rev 2013., 4CD003486
• [49]Rey-Santano C, Alvarez-Diaz FJ, Mielgo V, Murgia X, Lafuente H, Ruiz-Del-Yerro E, Valls-I-Soler A, Gastiasoro E: Bronchoalveolar lavage versus bolus administration of lucinactant, a synthetic surfactant in meconium aspiration in newborn lambs. Pediatr Pulmonol 2011, 46:991-999.
• [50]Benachi A, Chailley-Heu B, Barlier-Mur AM, Dumez Y, Bourbon J: Expression of surfactant proteins and thyroid transcription factor 1 in an ovine model of congenital diaphragmatic hernia. J Pediatr Surg 2002, 37:1393-1398.
• [51]Thébaud B, Barlier-Mur AM, Chailley-Heu B, Henrion-Caude A, Tibboel D, Dinh-Xuan AT, Bourbon JR: Restoring effects of vitamin A on surfactant synthesis in nitrofen-induced congenital diaphragmatic hernia in rats. Am J Respir Crit Care Med 2001, 164:1083-1089.
• [52]Kinsella JP, Greenough A, Abman SH: Bronchopulmonary dysplasia. Lancet 2006, 367:1421-1431.
• [53]Lally KP, Lally PA, Langham MR, Hirschl R, Moya FR, Tibboel D, Van Meurs K, Congenital Diaphragmatic Hernia Study Group: Surfactant does not improve survival rate in preterm infants with congenital diaphragmatic hernia. J Pediatr Surg 2004, 39:829-833.
• [54]Van Meurs K, Congenital Diaphragmatic Hernia Study Group: Is surfactant therapy beneficial in the treatment of the term newborn infant with congenital diaphragmatic hernia? J Pediatr 2004, 145:312-316.
• [55]Moya FR, Thomas VL, Romaguera J, Mysore MR, Maberry M, Bernard A, Freund M: Fetal lung maturation in congenital diaphragmatic hernia. Am J Obstet Gynecol 1995, 173:1401-1405.
• [56]Mysore MR, Margraf LR, Jaramillo MA, Breed DR, Chau VL, Arévalo M, Moya FR: Surfactant protein A is decreased in a rat model of congenital diaphragmatic hernia. Am J Respir Crit Care Med 1998, 157:654-657.
• [57]Boucherat O, Benachi A, Chailley-Heu B, Franco-Montoya ML, Elie C, Martinovic J, Bourbon JR: Surfactant maturation is not delayed in human fetuses with diaphragmatic hernia. PLoS Med 2007, 4:e237.
• [58]Janssen DJ, Zimmermann LJ, Cogo P, Hamvas A, Bohlin K, Luijendijk IH, Wattimena D, Carnielli VP, Tibboel D: Decreased surfactant phosphatidylcholine synthesis in neonates with congenital diaphragmatic hernia during extracorporeal membrane oxygenation. Intensive Care Med 2009, 35:1754-1760.
• [59]Awasthi S, Coalson JJ, Crouch E, Yang F, King RJ: Surfactant proteins A and D in premature baboons with chronic lung injury (Bronchopulmonary dysplasia): evidence for an inhibition of secretion. Am J Respir Crit Care Med 1999, 160:942-949.
• [60]Merrill JD, Ballard RA, Cnaan A, Hibbs AM, Godinez RI, Godinez MH, Truog WE, Ballard PL: Dysfunction of pulmonary surfactant in chronically ventilated premature infants. Pediatr Res 2004, 56:918-926.
• [61]Pandit PB, Dunn MS, Kelly EN, Perlman M: Surfactant replacement in neonates with early chronic lung disease. Pediatrics 1995, 95:851-854.
• [62]Laughon M, Bose C, Moya F, Aschner J, Donn SM, Morabito C, Cummings JJ, Segal R, Guardia C, Liu G, Surfaxin Study Group: A pilot randomized, controlled trial of later treatment with a peptide-containing, synthetic surfactant for the prevention of bronchopulmonary dysplasia. Pediatrics 2009, 123:89-96.
• [63]Sweet DG, Halliday HL: The use of surfactants in 2009. Arch Dis Child Educ Pract Ed 2009, 94:78-83.
• [64]Plavka R, Kopecký P, Sebron V, Leiská A, Svihovec P, Ruffer J, Dokoupilová M, Zlatohlávková B, Janus V, Keszler M: Early versus delayed surfactant administration in extremely premature neonates with respiratory distress syndrome ventilated by high-frequency oscillatory ventilation. Intensive Care Med 2002, 28:1483-1490.
• [65]The OSIRIS Collaborative Group: Early versus delayed neonatal administration of a synthetic surfactant - the judgement of OSIRIS: the OSIRIS collaborative group (open study of infants at high risk of or with respiratory insufficiency - the role of surfactant. Lancet 1992, 340:1363-1369.
• [66]Lefort S, Diniz EM, Vaz FA: Clinical course of premature infants intubated in the delivery room, submitted or not to porcine-derived lung surfactant therapy within the first hour of life. J Matern Fetal Neonatal Med 2003, 14:187-196.
• [67]Konishi M, Fujiwara T, Chida S, Maeta H, Shimada S, Kasai T, Fujii Y, Murakami Y: A prospective randomized trial of early versus late administration of a single dose of surfactant-TA. Early Hum Dev 1992, 29:275-282.
• [68]Gortner L, Wauer RR, Hammer H, Stock GJ, Heitmann F, Reiter HL, Kühl PG, Möller JC, Friedrich HJ, Reiss I, Hentschel R, Jorch G, Hieronimi G, Kuhls E: Early versus late surfactant treatment in preterm infants of 27 to 32 weeks’ gestational age: a multicenter controlled clinical trial. Pediatrics 1998, 102:1153-1160.
• [69]European Exosurf Study Group: Early or selective surfactant (Colfosceril Palmitate, Exosurf) for intubated babies at 26 to 29 weeks gestation: a European double-blind trial with sequential analysis. Online J Curr Clin Trials 1992. Doc No 28:[3886 words; 47 paragraphs]
• [70]Kandraju H, Murki S, Subramanian S, Gaddam P, Deorari A, Kumar P: Early routine versus late selective surfactant in preterm neonates with respiratory distress syndrome on nasal continuous positive airway pressure: a randomized controlled trial. Neonatology 2013, 103:148-154.
• [71]Dilmen U, Ozdemir R, Aksoy HT, Uras N, Demirel N, Kırimi E, Erdeve O, Ozer E, Baş AY, Gürsoy T, Zenciroğlu A, Ovalı F, Oğuz SS: Early regular versus late selective poractant treatment in preterm infants born between 25 and 30 gestational weeks: a prospective randomized multicentre study. J Matern Fetal Neonatal Med 2013. in press
• [72]British Association of Perinatal Medecine RDS/Surfactant Guidelines Group: Guidelines for good practice in the management of respiratory distress syndrome. 1999. http://www.bapm.org webcite
• [73]Engle WA, American Academy of Pediatrics Committee on Fetus and Newborn: Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics 2008, 121:419-432.
• [74]Fetus and Newborn Committee, Canadian Paediatric Society: Recommendations for neonatal surfactant therapy. Paediatr Child Health 2005, 10:109-116.
• [75]Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, Saugstad OD, Simeoni U, Speer CP, Halliday HL, European Association of Perinatal Medicine: European consensus guidelines on the management of neonatal respiratory distress syndrome in preterm infants - 2010 update. Neonatology 2010, 97:402-417.
• [76]Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, Saugstad OD, Simeoni U, Speer CP, Vento M, Halliday HL: European consensus guidelines on the management of neonatal respiratory distress syndrome in preterminfants - 2013 update. Neonatology 2013, 103:353-368.
• [77]Van Kaam AH, De Jaegere AP, Borensztajn D, Rimensberger PC, Neovent Study Group: Surfactant replacement therapy in preterm infants: a European survey. Neonatology 2011, 100:71-77.
• [78]Morley CJ, Davis PG, Doyle LW, Brion LP, Hascoet JM, Carlin JB, COIN Trial Investigators: Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 2008, 358:700-708.
• [79]Rojas MA, Lozano JM, Rojas MX, Laughon M, Bose CL, Rondon MA, Charry L, Bastidas JA, Perez LA, Rojas C, Ovalle O, Celis LA, Garcia-Harker J, Jaramillo ML, Colombian Neonatal Research Network: Very early surfactant without mandatory ventilation in premature infants treated with early continuous positive airway pressure: a randomized, controlled trial. Pediatrics 2009, 123:137-142.
• [80]Sandri F, Plavka R, Ancora G, Simeoni U, Stranak Z, Martinelli S, Mosca F, Nona J, Thomson M, Verder H, Fabbri L, Halliday H, CURPAP Study Group: Prophylactic or early selective surfactant combined with nCPAP in very preterm infants. Pediatrics 2010, 125:e1402-1409.
• [81]Finer NN, Carlo WA, Walsh MC, Rich W, Gantz MG, Laptook AR, Yoder BA, Faix RG, SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, et al.: Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 2010, 362:1970-1979.
• [82]Dunn MS, Kaempf J, de Klerk A, de Klerk R, Reilly M, Howard D, Ferrelli K, O’Conor J, Soll RF, Vermont Oxford Network DRM Study Group: Randomized trial comparing 3 approaches to the initial respiratory management of preterm neonates. Pediatrics 2011, 128:e1069-1076.
• [83]Vaucher YE, Peralta-Carcelen M, Finer NN, Carlo WA, Gantz MG, Walsh MC, Laptook AR, Yoder BA, SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, et al.: Neurodevelopmental outcomes in the early CPAP and pulse oximetry trial. N Engl J Med 2012, 367:2495-2504.
• [84]Bhandari V, Gavino RG, Nedrelow JH, Pallela P, Salvador A, Ehrenkranz RA, Brodsky NL: A randomized controlled trial of synchronized nasal intermittent positive pressure ventilation in RDS. J Perinatol 2007, 27:697-703.
• [85]Stevens TP, Harrington EW, Blennow M, Soll RF: Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev 2007., 4CD003063
• [86]Dani C, Corsini I, Bertini G, Pratesi S, Barp J, Rubaltelli FF: Effect of multiple INSURE procedures in extremely preterm infants. J Matern Fetal Neonatal Med 2011, 24:1427-1431.
• [87]Kirsten GF, Kirsten CL, Henning PA, Smith J, Holgate SL, Bekker A, Kali GT, Harvey J: The outcome of ELBW infants treated with NCPAP and InSurE in a resource-limited institution. Pediatrics 2012, 129:e952-959.
• [88]Kribs A: How best to administer surfactant to VLBW infants? Arch Dis Child Fetal Neonatal Ed 2011, 96:F238-240.
• [89]Kattwinkel J, Robinson M, Bloom BT, Delmore P, Ferguson JE: Technique for intrapartum administration of surfactant without requirement for an endotracheal tube. J Perinatol 2004, 24:360-365.
• [90]Abdel-Latif ME, Osborn DA: Pharyngeal instillation of surfactant before the first breath for prevention of morbidity and mortality in preterm infants at risk of respiratory distress syndrome. Cochrane Database Syst Rev 2011., 3CD008311
• [91]Trevisanuto D, Grazzina N, Ferrarese P, Micaglio M, Verghese C, Zanardo V: Laryngeal mask airway used as a delivery conduit for the administration of surfactant to preterm infants with respiratory distress syndrome. Biol Neonate 2005, 87:217-220.
• [92]Verder H, Agertoft L, Albertsen P, Christensen NC, Curstedt T, Ebbesen F, Greisen G, Hobolth N, Holm V, Jacobsen T, et al.: Surfactant treatment of newborn infants with respiratory distress syndrome primarily treated with nasal continuous positive air pressure: a pilot study. Ugeskr Laeger 1992, 154:2136-2139.
• [93]Göpel W, Kribs A, Ziegler A, Laux R, Hoehn T, Wieg C, Siegel J, Avenarius S, von der Wense A, Vochem M, Groneck P, Weller U, Möller J, Härtel C, Haller S, Roth B, Herting E, German Neonatal Network: Avoidance of mechanical ventilation by surfactant treatment of spontaneously breathing preterm infants (AMV): an open-label, randomised, controlled trial. Lancet 2011, 378:1627-1634.
• [94]Dargaville PA, Aiyappan A, Cornelius A, Williams C, De Paoli AG: Preliminary evaluation of a new technique of minimally invasive surfactant therapy. Arch Dis Child Fetal Neonatal Ed 2011, 96:F243-248.
• [95]Robillard E, Alarie Y, Dagenais-Perusse P, Baril E, Guilbeault A: Microaerosol administration of synthetic beta-gamma-dipalmitoyl-l-alpha-lecithin in the respiratory distress syndome: a preliminary report. Can Med Assoc J 1964, 90:55-57.
• [96]Chu J, Clements JA, Cotton EK, Klaus MH, Sweet AY, Tooley WH, Bradley BL, Brandorff LC: Neonatal pulmonary ischemia: I. clinical and physiological studies. Pediatrics 1967, 40:709-782.
• [97]Mazela J, Merritt TA, Finer NN: Aerosolized surfactants. Curr Opin Pediatr 2007, 19:155-162.
• [98]Lewis J, Ikegami M, Higuchi R, Jobe A, Absolom D: Nebulized vs. instilled exogenous surfactant in an adult lung injury model. J Appl Physiol 1991, 71:1270-1276.
• [99]Bahlmann H, Sun B, Nilsson G, Curstedt T, Robertson B: Aerosolized surfactant in lung-lavaged adult rats: factors influencing the therapeutic response. Acta Anaesthesiol Scand 2000, 44:612-622.
• [100]Lewis JF, Goffin J, Yue P, McCaig LA, Bjarneson D, Veldhuizen RA: Evaluation of exogenous surfactant treatment strategies in an adult model of acute lung injury. J Appl Physiol 1996, 80:1156-1164.
• [101]Ruppert C, Kuchenbuch T, Boensch M, Schmidt S, Mathes U, Hillebrand V, Henneke I, Markart P, Reiss I, Schermuly RT, Seeger W, Günther A: Dry powder aerosolization of a recombinant surfactant protein-C-based surfactant for inhalative treatment of the acutely inflamed lung. Crit Care Med 2010, 38:1584-1591.
• [102]Finer NN, Merritt TA, Bernstein G, Job L, Mazela J, Segal R: An open label, pilot study of Aerosurf® combined with nCPAP to prevent RDS in preterm neonates. J Aerosol Med Pulm Drug Deliv 2010, 23:303-309.
• [103]Shah S: Exogenous surfactant: intubated present, nebulized future? World J Pediatr 2011, 7:11-15.
• [104]Hentschel R, Jorch G: Acute side effects of surfactant treatment. J Perinat Med 2002, 30:143-148.
• [105]Raju TN, Langenberg P: Pulmonary hemorrhage and exogenous surfactant therapy: a metaanalysis. J Pediatr 1993, 123:603-610.
• [106]Bambang Oetomo S, Bos AF, de Lei L, Okken A, van Sonderen L, Halliday HL, Walti H: Immune response after surfactant treatment of newborn infants with respiratory distress syndrome. Biol Neonate 1993, 64:341-345.